21.03.2017
Carl Zeiss Meditec AG DE0005313704
DGAP-News: Carl Zeiss Meditec AG increases share capital by up to 10%
DGAP-News: Carl Zeiss Meditec AG / Key word(s): Capital Increase/Corporate
Action
Carl Zeiss Meditec AG increases share capital by up to 10%
21.03.2017 / 17:52
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Press Release
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE
UNITED STATES, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION IN WHICH
THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.
Carl Zeiss Meditec AG increases share capital by up to 10%
Proceeds from the offering will be used to accelerate Company's growth
strategy
JENA, 21 March 2017
Carl Zeiss Meditec AG has resolved on a cash capital increase from
authorized capital of up to 10% minus one share. In total up to 8,130,960
new shares will be offered to institutional investors by way of an
accelerated bookbuilding process with the exclusion of subscription rights.
The Company plans to use the proceeds to accelerate its growth strategy. Dr.
Ludwin Monz, President and CEO of Carl Zeiss Meditec AG, states: "Given the
current dynamics and consolidation trends in our markets, we see significant
opportunities in the short to medium term to accelerate our growth through
selective acquisitions. A number of projects in different size brackets are
being considered, for which we aim to substantially increase our financial
power and flexibility with the current transaction, improving our position
for potential future acquisitions. We continuously aim to further expand our
already very successful strategy as a global solutions provider in
ophthalmology and microsurgery with additional growth initiatives."
The new shares will carry full dividend rights for the past fiscal year
2015/16 and will be offered for purchase exclusively to institutional
investors in a private placement by way of an accelerated bookbuilding
process, which starts immediately following publication of this press
release. The Company reserves the right to close the order book at any time.
Carl Zeiss AG will not subscribe for any shares in the contemplated capital
increase. Thus, the free float will increase from 35% up to approximately
41% and thereby market liquidity of the Carl Zeiss Meditec AG share will be
broadened. Carl Zeiss AG will remain a long-term majority shareholder in
Carl Zeiss Meditec AG.
Joh. Berenberg, Gossler & Co. KG and Commerzbank AG act as Joint Global
Coordinators and Joint Bookrunners for the transaction.
Contact for media and investors
Sebastian Frericks
Director Investor Relations Carl Zeiss Meditec AG
Tel. +49 (0)3641 220 116
E-mail: [email protected]
www.zeiss.de/presse
Forward-Looking Statements
This news release may contain forward-looking statements based on current
assumptions and forecasts made by Carl Zeiss Meditec AG management. Various
known and unknown risks, uncertainties and other factors could lead to
material differences between the actual future results, financial situation,
development or performance of the company and the estimates given here. The
company assumes no liability whatsoever to update these forward-looking
statements or to confirm them to future events or developments.
Notice
This publication does not constitute a public offer of securities in
Germany. It is not for publication or distribution, directly or indirectly,
in or into the United States of America, Canada, Australia, or any other
jurisdiction in which the distribution or release would be unlawful. This
publication does not constitute a prospectus, an offer to sell securities,
or a solicitation of an offer to buy securities, in the United States of
America or in any other jurisdiction to any person to whom it is unlawful to
make such offer or solicitation in such jurisdiction. Securities may not be
offered or sold in the United States of America absent registration or an
exemption from registration under the U.S. Securities Act of 1933, as
amended (the 'Securities Act'). The securities of Carl Zeiss Meditec AG
described herein have not been and will not be registered under the
Securities Act, or the laws of any state or territory of the United States,
and may not be offered or sold within the United States of America, except
pursuant to an exemption from, or in a transaction not subject to, the
registration requirements of the Securities Act and applicable state laws.
Carl Zeiss Meditec AG does not intend to register any portion of the
offering in the United States of America or conduct a public offering of
securities in the United States of America.
Brief profile
Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX of
the German stock exchange, is one of the world's leading medical technology
companies. The Company supplies innovative technologies and
application-oriented solutions designed to help doctors improve the quality
of life of their patients. The Company offers complete solutions, including
implants and consumables, to diagnose and treat eye diseases. The Company
creates innovative visualization solutions in the field of microsurgery. In
fiscal year 2015/2016 (ended 30 September) the Group's 2,900 employees
generated revenue of EUR1,088 million.
The Group's head office is located in Jena, Germany, and it has subsidiaries
in Germany and abroad; more than 50 percent of its employees are based in
the USA, Japan, Spain and France. The Center for Application and Research
(CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for
Research and Development in Shanghai, China, strengthen the Company's
presence in these rapidly developing economies. Around 35 percent of Carl
Zeiss Meditec AG's shares are in free float. The remaining approx. 65
percent are held by Carl Zeiss AG, one of the world's leading companies in
the optical and optoelectronic industries.
For more information visit our website at: www.zeiss.com
---------------------------------------------------------------------------
21.03.2017 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Carl Zeiss Meditec AG
Göschwitzer Str. 51-52
07745 Jena
Germany
Phone: +49 (0)3641 220-0
Fax: +49 (0)3641 220-112
E-mail: [email protected],[email protected]
Internet: www.meditec.zeiss.de
ISIN: DE0005313704
WKN: 531370
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
556655 21.03.2017
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Carl Zeiss Meditec AG ISIN: DE0005313704 können Sie bei EQS abrufen
Medtech , 531370 , AFX , XETR:AFX